TMO Add to watchlist $531.67 +4.45 (+0.84%) Last updated: Apr 16, 2026 00:56
52-Week Range
$531.67
$385.46 $531.67 $643.99

Fundamentals Overview

Thermo Fisher Scientific Inc. is in the middle of its 52-week range with premium valuation, trading relatively flat today.

Valuation premium

P/E 29.9 PEG 4.99 P/B 3.74 P/S 4.43

Intrinsic value (DCF)

-0.4% downside vs price

Profitability

Net margin 15.1%

Risk (Beta)

0.97 — in line vol

Earnings & growth

EPS $17.81 Rev +9.8% Profit +22.2% vs prior qtr

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Hold — 52% confidence Risk: Moderate Volatility — Beta 0.97. Diversify and only invest what you can afford to lose.

Supporting (Buy):

Analyst grade: B+ · Sentiment improving (5 upgrades)

Pressures (Sell):

3M vs S&P 500: -14.3% · 3M vs Healthcare sector: -7.5%

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$197.51B
P/E (TTM)
29.85
EPS (TTM)
$17.81
Dividend Yield
0.33%
52-Week Range
$385.46 - $643.99
Volume vs Avg
N/A
Beta
0.97

About

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic science...
Sector: Healthcare
Headquarters: US
Employees: 125,000
IPO Date: Mar 1980
Beta: 0.97 (Less volatile than market)

Ratings & Grades at a Glance

Overall rating: B+. Recent institutional grades: majority upgrades. Current institutional positions: Buy: 8, Equal Weight: 1, Neutral: 3, Outperform: 6, Overweight: 11, Sector Outperform: 1.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $529.64; current price is $531.67. That’s a -0.4% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 29.85
DCF value (model) $529.64 (-0.4% vs price)
PEG (TTM) 4.99
P/B (TTM) 3.74
P/S (TTM) 4.43
P/FCF (TTM) 31.39
Liquidity & enterprise
Current Ratio (TTM) 1.89
Quick Ratio (TTM) 1.53
Cash Ratio (TTM) 0.65
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 15.07%
Gross margin (TTM) 39.46%
Operating margin (TTM) 17.96%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for TMO.

Analyst Sentiment at a Glance

B+ Sentiment Improving
Buy 8Equal Weight 1Neutral 3Outperform 6Overweight 11Sector Outperform 1
5 upgrades, 0 downgrades
Price Target Consensus
Current $531.67
Median $653.00
Consensus $657.45
Low consensus $580.00
High consensus $750.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Evercore ISI Group maintain Outperform Outperform 2026-04-06
Barclays maintain Overweight Overweight 2026-01-30
TD Cowen maintain Buy Buy 2026-01-30
Citigroup maintain Buy Buy 2026-01-30
Stifel maintain Buy Buy 2026-01-09
TD Cowen maintain Buy Buy 2026-01-07
Wells Fargo maintain Overweight Overweight 2025-12-15
Citigroup upgrade Neutral Buy 2025-12-11
Keybanc upgrade Sector Weight Overweight 2025-12-08
Morgan Stanley maintain Overweight Overweight 2025-12-02
HSBC upgrade Hold Buy 2025-12-01
Argus Research maintain Buy Buy 2025-10-29
Morgan Stanley maintain Overweight Overweight 2025-10-28
TD Cowen maintain Buy Buy 2025-10-23
Wells Fargo maintain Overweight Overweight 2025-10-23
UBS maintain Neutral Neutral 2025-10-23
Citigroup maintain Neutral Neutral 2025-10-23
Barclays maintain Overweight Overweight 2025-10-23
Leerink Partners maintain Outperform Outperform 2025-10-22
JP Morgan maintain Overweight Overweight 2025-10-09
Evercore ISI Group maintain Outperform Outperform 2025-10-07
Barclays maintain Overweight Overweight 2025-10-02
Barclays upgrade Equal Weight Overweight 2025-09-11
Barclays maintain Equal Weight Equal Weight 2025-07-24
Baird maintain Outperform Outperform 2025-07-24
UBS maintain Neutral Neutral 2025-07-24
Wells Fargo maintain Overweight Overweight 2025-07-24
Raymond James maintain Outperform Outperform 2025-07-24
Baird maintain Outperform Outperform 2025-07-18
Scotiabank upgrade Sector Perform Sector Outperform 2025-07-11